0. DOCID:27511 SCORE: 0.00304741975270257
DOCNO: 9560835
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: genetics
AUTHOR: S E DePasquale SE
AUTHOR: A Giordano A
AUTHOR: A E Donnenfeld AE
AFFILIATION: Program in Woman's Oncology, Woman and Infants Hospital, Providence, RI 02905-2499, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Obstetrical & gynecological survey.
COUNTRY: UNITED STATES
TITLE: The genetics of ovarian cancer: molecular biology and clinical application.
PUBDATE: 19980401
Ovarian cancer is the fifth most common malignancy among American women and the fourth leading cause of cancer death. The rapid advances in molecular genetic analysis, presymptomatic detection, and treatment of ovarian cancer are staggering. In this review, both the genetic component and the molecular biology of ovarian cancer are discussed, as well as current recommendations for genetic counseling. It is important for the practicing obstetrician and gynecologist to become familiar with these concepts, for it is he or she who will likely serve as a primary resource of information for these patients.


1. DOCID:27907 SCORE: 0.00303936866054212
DOCNO: 10977932
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: pathology
QUALIFIER: pathology
QUALIFIER: pathology
AUTHOR: G I Nepomnyashchikh GI
AUTHOR: V A Levitskii VA
AUTHOR: L M Nepomnyashchikh LM
AUTHOR: S V Aidagulova SV
AUTHOR: L A Naumova LA
AUTHOR: I Y Belov IY
AFFILIATION: Laboratory of Ultrastructural Basis of Pathology, Institute of Regional Pathology and Pathomorphology, Siberian Division of Russian Academy of Medical Sciences, Novosibirsk.
PUBTYPE: Journal Article
JOURNALTITLE: Bulletin of experimental biology and medicine.
COUNTRY: United States
TITLE: Instability of bronchial epithelium in chronic pulmonary diseases.
PUBDATE: 20000401
Pathomorphological examination of large bronchi in patients with occupational diseases, lung cancer, and in subjects exposed to radiation revealed structural and functional heterogeneity of the epithelium: the presence of focal atrophy, metaplasia, hyper- and dysplasia in the same biopsy specimen. This phenomenon was termed as instability of the epithelium. Thickness of the epithelium greatly varied, especially, in neoplastic processes. Atrophy and epithelial instability phenomenon are interpreted as morphological markers of ecological and oncological risk.


2. DOCID:27971 SCORE: 0.00303936812577775
DOCNO: 10854151
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Genetic Vectors
QUALIFIER: genetics
QUALIFIER: therapy
QUALIFIER: therapy
QUALIFIER: methods
AUTHOR: L C Pagliaro LC
AFFILIATION: Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA. lpagliar@mdanderson.org
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: World journal of urology.
COUNTRY: GERMANY
TITLE: Gene therapy for bladder cancer.
PUBDATE: 20000401
Tumor-suppressor genes can be transferred into tumor cells in vivo using a replication-defective adenoviral vector. P53 mutations are frequent in bladder cancer, and adenovirus-mediated p53 gene transfer is growth-inhibitory to bladder cancer cells in vitro. The vector Ad5CMV-P53, which contains human wild-type p53, is being administered intravesically to patients with bladder cancer in a phase I clinical trial. The results of this study will provide the basis for phase II and phase III trials in which gene therapy will be integrated with existing therapies for improved local control and opportunities for bladder preservation.


3. DOCID:27968 SCORE: 0.00303936766963476
DOCNO: 11561985
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
AUTHOR: R Dreicer R
AFFILIATION: Department of Hematology, The Urologic Institute, Cleveland Clinic Foundation, OH 44195, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Seminars in urologic oncology.
COUNTRY: United States
TITLE: Neoadjuvant chemotherapy in the management of muscle-invasive bladder cancer.
PUBDATE: 20010801
Muscle-invasive bladder cancer is typically an aggressive solid tumor with the propensity for early systemic dissemination. Although radical cystectomy remains the gold standard intervention, the high rate of systemic failure has prompted investigators to evaluate various strategies to attempt to improve survival, including the early administration of systemic chemotherapy. These efforts have provided mixed results with two recently completed trials providing conflicting results. Other strategies include attempts to both preserve the bladder using combinations of limited surgical resection, systemic chemotherapy, and radiotherapy. This review focuses on the potential of neoadjuvantly administered therapies to impact the management of muscle-invasive bladder cancer.


4. DOCID:19729 SCORE: 0.0028827006095759
DOCNO: 2338953
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: diagnosis
AUTHOR: P M Go PM
AUTHOR: H Obertop H
AUTHOR: G Blijham G
AUTHOR: J D Munting JD
AFFILIATION: Afd. Algemene Heelkunde, Academisch Ziekenhuis, Maastricht.
PUBTYPE: Journal Article
JOURNALTITLE: Nederlands tijdschrift voor geneeskunde.
COUNTRY: NETHERLANDS
TITLE: [Breast carcinoma in women younger than 30 years]
PUBDATE: 19900401
Breast cancer is rare in females younger than 30 years. In a retrospective study of 25 women the effects of the early age on diagnosis, treatment and prognosis were investigated. In 21 women there was a clinical or radiological suspicion of carcinoma. Nevertheless, a delay in diagnosis was found in 9 of the 21 patients. In 16 patients stage I tumour was found, in 7 stage II, in I stage III and in I stage IV. After an average follow-up period of 68 months, 20 patients had no tumour recurrence. Tumour stage, treatment and prognosis were comparable with the characteristics reported for other age groups.


5. DOCID:26965 SCORE: 0.00280172185847864
DOCNO: 10048254
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Patient Selection
QUALIFIER: therapeutic use
QUALIFIER: complications
QUALIFIER: drug therapy
AUTHOR: C Hassed C
AFFILIATION: Monash University Department of Community Medicine.
PUBTYPE: Journal Article
JOURNALTITLE: Australian family physician.
COUNTRY: AUSTRALIA
TITLE: Choosing an opioid analgesic for cancer patients.
PUBDATE: 19990201
The following is a supplement to the article on the management of cancer pain which appeared in the January edition of AFP. It will provide some more detailed information on the choice and prescribing of opioid analgesics other than morphine for cancer patients. One should, of course, bear in mind many of the comments made in the original article regarding the holistic assessment of patients and their pain, the use of adjuvant therapies and alternatives. For more complete information regarding their use and pharmacokinetics one may need to consult product information, MIMS or one of the excellent short books designed for GPs.


6. DOCID:23746 SCORE: 0.00276680153712798
DOCNO: 8623719
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Postmenopause
DESCRIPTOR: Vagina
QUALIFIER: ultrasonography
AUTHOR: A M Weissman AM
AUTHOR: T J Barloon TJ
AFFILIATION: Department of Family Practice, University of Iowa College of Medicine, Iowa City 52242, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: American family physician.
COUNTRY: UNITED STATES
TITLE: Transvaginal ultrasonography in nonpregnant and postmenopausal women.
PUBDATE: 19960501
Compared with transabdominal pelvic ultrasonography, transvaginal ultrasonography provides improved resolution for visualization of female pelvic organs, with less artifact. Transvaginal ultrasonography has superseded the transabdominal approach in many situations. Identification of uterine and adnexal masses can be facilitated with use of transvaginal ultrasonography. Transvaginal ultrasonography is also useful in the evaluation of pelvic pain and suspected pelvic inflammatory disease. Postmenopausal patients with vaginal bleeding or a palpable ovary can be triaged on the basis of transvaginal ultrasonographic findings, avoiding invasive diagnostic procedures in selected patients. Screening average-risk patients for ovarian cancer is not an accepted indication for transvaginal ultrasonography at this time.


7. DOCID:23856 SCORE: 0.00275134020908748
DOCNO: 7602777
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: analysis
QUALIFIER: analysis
AUTHOR: T Hayakawa T
AUTHOR: S Naruse S
AUTHOR: M Kitagawa M
AUTHOR: T Kondo T
AFFILIATION: 2nd Department of Internal Medicine, Nagoya University School of Medicine.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Nippon rinsho. Japanese journal of clinical medicine.
COUNTRY: JAPAN
TITLE: [Elastase]
PUBDATE: 19950501
Elastases are unique among the proteases in that they are capable of hydrolyzing the scleroprotein elastin. The enzymes include pancreatic elastases 1 (Protease E) and 2, and neutrophil elastase. These three elastases also have esterase and amidase activity toward synthetic substrates such as succinyl-trialanine-p-nitroanilide. Although the three enzymes are similar to each other in enzyme activity, they are quite different in immunoactivity. Therefore, each elastase has its own specific immunoassay either by RIA or EIA. Serum immunoreactive pancreatic elastases reflect disease conditions of pancreatic diseases, especially acute pancreatitis and pancreatic cancer. On the other hand, serum neutrophil elastase increases in various inflammatory diseases or conditions.


8. DOCID:18062 SCORE: 0.00272253102133966
DOCNO: 1609218
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapy
AUTHOR: J P Droz JP
AUTHOR: A Kramar A
AUTHOR: P Wibault P
AUTHOR: J J Perrin JJ
AUTHOR: A Roche A
AUTHOR: B Escudier B
AUTHOR: G Missenard G
AUTHOR: B H Court BH
AFFILIATION: D├ępartement de M├ędecine, Institut Gustave-Roussy, Villejuif.
PUBTYPE: Journal Article
JOURNALTITLE: La Revue du praticien.
COUNTRY: FRANCE
TITLE: [Therapeutic strategy in metastatic renal cancer]
PUBDATE: 19920501
Prognostic factors have been described in metastatic renal cell cancer: performance status, weight loss, elevated erythrocyte sedimentation rate, presence of liver metastases. The treatment for a patient with good prognosis consists of: surgical exeresis of solitary metastasis, immunotherapy by either interferon or interleukin 2. Treatment in case of a rom prognosis is a combination of supportive care, orthopedic surgery for pathologic fracture or medullar compression, antalgic radiotherapy, embolization, nephrectomy for hematuria, and analgesic treatments.


9. DOCID:21384 SCORE: 0.0026727349084393
DOCNO: 8741467
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Stents
QUALIFIER: complications
QUALIFIER: therapy
AUTHOR: T Ojika T
AUTHOR: N Mukouyama N
AUTHOR: T Murata T
AUTHOR: H Hasegawa H
AFFILIATION: Department of Thoracic Surgery, Nagoya Daini Red Cross Hospital, Japan.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Kyobu geka. The Japanese journal of thoracic surgery.
COUNTRY: JAPAN
TITLE: [A case report of relapsed esophageal cancer with tracheal stenosis treated with expandable metallic stent placement]
PUBDATE: 19960801
A 63-year-old male who suffered from relapsed esophageal cancer in the thoracic lymphonode causing severe tracheal stenosis, was treated by expandable metallic stent (EMS) placement. Dyspnea has disappeared immediately after EMS placement and the patient has been free from dyspnea until his death. EMS has been very effective for the therapy of tracheal stenosis by esophageal cancer.


10. DOCID:21412 SCORE: 0.00267273309165572
DOCNO: 8858767
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Gene Therapy
DESCRIPTOR: Pediatrics
DESCRIPTOR: Surgery
AUTHOR: M L Brandt ML
AFFILIATION: Department of Surgery, Baylor College of Medicine, Houston, TX, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Seminars in pediatric surgery.
COUNTRY: UNITED STATES
TITLE: Gene therapy in pediatric surgery.
PUBDATE: 19960801
Gene transfer has become a reality during the last decade. The basic principles of molecular biology, gene transfer, and the problems associated with this new technology have direct implications for the treatment of pediatric surgical patients. Research into applications of gene transfer in the treatment of disorders of the bone marrow, cancer, hemophilia, hepatic and metabolic disease, cystic fibrosis, and vascular disease is rapidly progressing. These areas of research may dramatically affect the care of pediatric surgical patients in the future.


11. DOCID:31048 SCORE: 0.00265792404514176
DOCNO: 15993065
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: chemical synthesis
QUALIFIER: chemistry
QUALIFIER: chemical synthesis
AUTHOR: Timothy A Blizzard TA
AUTHOR: Frank DiNinno F
AUTHOR: Helen Y Chen HY
AUTHOR: Seongkon Kim S
AUTHOR: Jane Y Wu JY
AUTHOR: Wanda Chan W
AUTHOR: Elizabeth T Birzin ET
AUTHOR: Yi Tien Yang YT
AUTHOR: Lee-Yuh Pai LY
AUTHOR: Edward C Hayes EC
AUTHOR: Carolyn A DaSilva CA
AUTHOR: Susan P Rohrer SP
AUTHOR: James M Schaeffer JM
AUTHOR: Milton L Hammond ML
AFFILIATION: Merck Research Laboratories, RY800-B116, P.O. Box 2000, Rahway, NJ 07065, USA. tim.blizzard@merck.com
PUBTYPE: Journal Article
JOURNALTITLE: Bioorganic & medicinal chemistry letters.
COUNTRY: England
TITLE: Estrogen receptor ligands. Part 13: Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain.
PUBDATE: 20050901
An optimized side chain for dihydrobenzoxathiin SERAMs was discovered and attached to four dihydrobenzoxathiin platforms. The novel SERAMs show exceptional estrogen antagonist activity in uterine tissue and an MCF-7 breast cancer cell assay.


12. DOCID:31137 SCORE: 0.00265792312014053
DOCNO: 16143160
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: analogs & derivatives
QUALIFIER: drug therapy
AUTHOR: Howard A Burris HA
AFFILIATION: The Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville, USA. hburris@tnonc.com
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Seminars in oncology.
COUNTRY: United States
TITLE: Recent updates on the role of chemotherapy in pancreatic cancer.
PUBDATE: 20050801
Single-agent gemcitabine remains the standard treatment for advanced pancreatic cancer. Recent phase III trials have failed to show improvements in survival using gemcitabine in combination with other chemotherapeutic agents, although the gemcitabine/oxaliplatin combination has shown some promise. The combination of gemcitabine with erlotinib was associated with a significant prolongation of survival. Promising results in a phase II trial of gemcitabine in combination with bevacizumab have led to a randomized comparative trial of the combination. Potential combinations with other biologic agents are being investigated.


13. DOCID:29408 SCORE: 0.00263601839814681
DOCNO: 16281265
OWNER: NLM
STATUS: In-Process
AUTHOR: Philippe Vignal P
PUBTYPE: Journal Article
JOURNALTITLE: Journal of clinical ultrasound : JCU.
COUNTRY: United States
TITLE: Sonographic appearance of a carcinoma developed in ectopic axillary breast tissue.
PUBDATE: 20051201
Primary breast cancer of ectopic axillary breast tissue is almost never diagnosed preoperatively. When not accompanied by nipple-areolar complex, the mass is often believed to be a lipoma, an enlarged lymph node, or a skin lesion such as a sebaceous cyst or hydradenitis suppurativa. When an axillary mass is found, a percutaneous needle biopsy is mandatory to rule out the diagnosis of cancer in ectopic breast tissue. We describe the sonographic findings of a case of ductal carcinoma in axillary ectopic breast tissue.


14. DOCID:19455 SCORE: 0.00259125340425354
DOCNO: 8112159
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: surgery
QUALIFIER: surgery
AUTHOR: M T Yang MT
AFFILIATION: Tumor Hospital of Sun Yatsen University of Medical Sciences, Guangzhou.
PUBTYPE: Journal Article
JOURNALTITLE: Zhonghua wai ke za zhi [Chinese journal of surgery].
COUNTRY: CHINA
TITLE: [Treatment of male breast cancer: an analysis of 41 cases]
PUBDATE: 19930501
41 male patients with breast cancer confirmed pathologically were treated. Of these, 35 were treated by radical mastectomy and 6 by modified radical mastectomy. The patients with axillary lymphatic metastasis were treated by postoperative radiotherapy, chemotherapy. The overall 5-, 10- and 15-year survival rates were 67.6%, 53.3% and 55.0%, respectively. The 15 year survival rates of TNM stage I-II and III patients were 55% and 50% respectively. We conclude that radical or modified radical mastectomy is the rational therapy for male breast cancer. The patients in stage III will benefit from postoperative adjuvant therapy in terms of improving prognosis.